Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

Bivalent BCMA Binding and Low Affinity CD3 T-Cell Engagement By Abbv-383 Drives Sustained Activation with Reduced T-Cell Exhaustion in Preclinical Models of Multiple Myeloma

David Sharon, Valerie Robinson, Claudie Hecquet, Kelly Calabrese, Cormac Cosgrove, Christine Mantis, Orlando Bueno, Aarif Ahsan, Adam Chervin, PK Epling-Burnette, Jeremy A Ross

Blood (2023) 142 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2023-179039

Published: 2023

Journal Articles

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Akshanth R Polepally, Carla Biesdorf, Muhammad Erfan Uddin, Nils Boehm, Jeremy A Ross, Shaji Kunnathu Kumar, Peter M. Voorhees, Anita D'Souza, Katja Weisel, Orlando Bueno, Chetasi Talati, Rajeev M Menon

Blood (2023) 142 (Supplement 1): 6722.

https://doi.org/10.1182/blood-2023-180127

Published: 2023

Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2023-182388

Published: 2023

Journal Articles

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Nizar J Bahlis, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Niels Abildgaard, Jacob Laubach, Vincent Ribrag, Peter M. Voorhees, Xifeng Wang, Orlando Bueno, Yan Luo, Jeremy A Ross, Jonathan L. Kaufman

Blood (2023) 142 (Supplement 1): 338.

https://doi.org/10.1182/blood-2023-180766

Published: 2023

Journal Articles

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Sandra Basic - Kinda, Roman Hajek, Ankit Pahwa, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy A. Ross, Carlos Hader

Blood (2022) 140 (Supplement 1): 12481–12482.

https://doi.org/10.1182/blood-2022-159677

Published: 2022

Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 7326–7327.

https://doi.org/10.1182/blood-2022-157977

Published: 2022

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

Genomic Landscape of t(11;14) in Multiple Myeloma

Jeremy A. Ross, Herve Avet-Loiseau, Xiaotong Li, Raphaele Thiebaut-Millot, Carlos Hader

Blood (2022) 140 (Supplement 1): 10092–10093.

https://doi.org/10.1182/blood-2022-167167

Published: 2022

Journal Articles

A Sensitive Machine Learning-Based Approach to Assess Multiple Myeloma t(11;14) Genetic Subtype from Histopathology Images

Adam Stanford-Moore, Yi Liu, Chandan Akiti, Ali Behrooz, Bahar Rahsepar, Benjamin Glass, Aditee Shrotre, Jeremy A. Ross, Dorothy French

Blood (2022) 140 (Supplement 1): 7846–7847.

https://doi.org/10.1182/blood-2022-159522

Published: 2022

Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Blood (2022) 140 (Supplement 1): 4242–4244.

https://doi.org/10.1182/blood-2022-160195

Published: 2022

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Sudeep Karve, Shaji Kumar, Veronica Gonzalez De La Calle, Silvia Mangiacavalli, Chang-Ki Min, Efstathios Kastritis, Graca Esteves, Michel Delforge, Fernando Escalante, Jin Lu, Yang Liu, Max Bittrich, Charalampia Kyriakou, Andrew J. Yee, Emma Arriola, Jeremy A. Ross, Shivaji Manthena, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2021-149336

Published: 2021

Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau

Blood (2021) 138 (Supplement 1): 84.

https://doi.org/10.1182/blood-2021-145757

Published: 2021

Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 817.

https://doi.org/10.1182/blood-2021-146043

Published: 2021

Journal Articles

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Nizar J. Bahlis, Jonathan L. Kaufman, Rachid Baz, Hang Quach, Shir-Jing Ho, Annette J. Vangsted, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Orlando F. Bueno, Yan Luo, Christine Mantis, Deeksha Vishwamitra, Jeremy A. Ross, Simon J Harrison

Blood (2021) 138 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2021-146012

Published: 2021

Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134737

Published: 2020

Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-134924

Published: 2020

Journal Articles

Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry

David Kimmel, BSc,Mlt, Mohammed A Aljama, MBBS,FRCPC, Stephen Ronan Foley, MD FRCPC, Hira S Mian, MD, Catherine A Ross, MD MSc ,FRCPC

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141060

Published: 2020

NARROW

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Bivalent BCMA Binding and Low Affinity CD3 T-Cell Engagement By Abbv-383 Drives Sustained Activation with Reduced T-Cell Exhaustion in Preclinical Models of Multiple Myeloma

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Genomic Landscape of t(11;14) in Multiple Myeloma

A Sensitive Machine Learning-Based Approach to Assess Multiple Myeloma t(11;14) Genetic Subtype from Histopathology Images

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only